ECCO 2016 Oral Presentation 024. Mucosal healing and dysplasia surveillance in a large referral centre cohort of patients with Crohn’s Disease and Ulcerative Colitis treated with Vedolizumab

M. Noman1, M. Ferrante1, R. Bisschops1, G. De Hertogh2, K. van den Broeck1, K. Rans1, P. Rutgeerts1, S. Vermeire1, G. van Assche1

1UZ Leuven, Gastroenterology, Leuven, Belgium, 2UZ Leuven, Campus Gasthuisberg, Pathology, Leuven, Belgium

Results: Of 118 initially recruited patients in the GEMINI LTS study, 68 patients (29 CD/39 UC) received vedolizumab beyond 1 year. Median treatment duration was 38 (range 13–73) months. Endoscopy data were available for 23 CD and 34 UC patients. At the last colonoscopy, 70% of UC patients maintained mucosal healing. In CD, 44% had complete and 38% had partial healing. In a total of 32 (CD) and 50 (UC) colonoscopies throughout the study and performed after a median of 2.7 years, Mayo score 0 (UC) and complete healing (CD) was observed in 54% and 44%, respectively. Low-grade dysplasia (LGD) was detected in 10% of patients. No high-grade dysplasia (HGD) or colorectal cancer was found in biopsies or resected lesions, although HGD was found in the colectomy specimen of a refractory patient with LGD in biopsies.

Conclusion: Long-term endoscopic healing is observed in a selected group of CD and UC patients treated with vedolizumab. Although even larger cohorts are needed, no new colonic dysplasia signal was found in this study.